Misplaced Pages

Phentolamine: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 19:39, 5 August 2011 edit216.16.251.21 (talk) →Uses← Previous edit Revision as of 03:04, 30 August 2011 edit undoBogBot (talk | contribs)Bots53,132 edits populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBotNext edit →
Line 1: Line 1:
{{drugbox {{Drugbox
| Watchedfields = changed | Watchedfields = changed
| verifiedrevid = 418037369 | verifiedrevid = 418037369
Line 5: Line 5:
| image = Phentolamine Structural Formulae.svg | image = Phentolamine Structural Formulae.svg
| image2 = Phentolamine-space-filling.png | image2 = Phentolamine-space-filling.png

<!--Clinical data-->
| tradename = Regitine
| Drugs.com = {{drugs.com|CONS|phentolamine}}
⚫ | pregnancy_category = C <small>(])
⚫ | legal_status =
⚫ | routes_of_administration = Usually IV or IM

<!--Pharmacokinetic data-->
⚫ | bioavailability =
⚫ | protein_bound =
⚫ | metabolism = Hepatic
⚫ | elimination_half-life = 19 minutes

<!--Identifiers-->
⚫ | CASNo_Ref = {{cascite|correct|CAS}}
⚫ | CAS_number = 50-60-2
⚫ | ATC_prefix = C04
⚫ | ATC_suffix = AB01
⚫ | ATC_supplemental = {{ATC|V03|AB36}}
⚫ | PubChem = 5775
⚫ | IUPHAR_ligand = 502
⚫ | DrugBank = APRD00615
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5571 | ChemSpiderID = 5571
| UNII_Ref = {{fdacite|correct|FDA}} | UNII_Ref = {{fdacite|correct|FDA}}
| UNII = Z468598HBV | UNII = Z468598HBV
⚫ | KEGG_Ref = {{keggcite|correct|kegg}}
⚫ | InChI = 1/C17H19N3O/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15/h2-8,11,21H,9-10,12H2,1H3,(H,18,19)
⚫ | KEGG = D08362
⚫ | InChIKey = MRBDMNSDAVCSSF-UHFFFAOYAI
⚫ | smiles = Oc3cc(N(c1ccc(cc1)C)CC/2=N/CCN\2)ccc3
| ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 597 | ChEMBL = 597

<!--Chemical data-->
⚫ | C=17 | H=19 | N=3 | O=1
⚫ | molecular_weight = 281.352 g/mol
⚫ | smiles = Oc3cc(N(c1ccc(cc1)C)CC/2=N/CCN\2)ccc3
⚫ | InChI = 1/C17H19N3O/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15/h2-8,11,21H,9-10,12H2,1H3,(H,18,19)
⚫ | InChIKey = MRBDMNSDAVCSSF-UHFFFAOYAI
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H19N3O/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15/h2-8,11,21H,9-10,12H2,1H3,(H,18,19) | StdInChI = 1S/C17H19N3O/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15/h2-8,11,21H,9-10,12H2,1H3,(H,18,19)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MRBDMNSDAVCSSF-UHFFFAOYSA-N | StdInChIKey = MRBDMNSDAVCSSF-UHFFFAOYSA-N
⚫ | CAS_number = 50-60-2
⚫ | CASNo_Ref = {{cascite|correct|CAS}}
⚫ | ATC_prefix = C04
⚫ | ATC_suffix = AB01
⚫ | ATC_supplemental = {{ATC|V03|AB36}}
⚫ | PubChem = 5775
⚫ | IUPHAR_ligand = 502
⚫ | DrugBank = APRD00615
⚫ | KEGG_Ref = {{keggcite|correct|kegg}}
⚫ | KEGG = D08362
⚫ | C = 17 | H = 19 | N = 3 | O = 1
⚫ | molecular_weight = 281.352 g/mol
⚫ | bioavailability =
⚫ | protein_bound =
⚫ | metabolism = Hepatic
⚫ | elimination_half-life = 19 minutes
⚫ | pregnancy_category = C <small>(])
</small>
⚫ | legal_status =
⚫ | routes_of_administration = Usually IV or IM
}} }}
'''Phentolamine''' (Regitine) is a reversible<ref name="isbn0-7817-4266-8">{{cite book |author=Jewell, John R.; Longworth, David L.; Stoller, James K.; Casey, David |title=The Cleveland Clinic internal medicine case reviews |publisher=Lippincott Williams & Wilkins |location=Hagerstown, MD |year=2003 |isbn=0-7817-4266-8 |oclc= |doi= |accessdate= |page=32}}</ref> nonselective alpha-]. <ref>{{MeshName|Phentolamine}}</ref> '''Phentolamine''' (Regitine) is a reversible<ref name="isbn0-7817-4266-8">{{cite book |author=Jewell, John R.; Longworth, David L.; Stoller, James K.; Casey, David |title=The Cleveland Clinic internal medicine case reviews |publisher=Lippincott Williams & Wilkins |location=Hagerstown, MD |year=2003 |isbn=0-7817-4266-8 |oclc= |doi= |accessdate= |page=32}}</ref> nonselective alpha-]. <ref>{{MeshName|Phentolamine}}</ref>

Revision as of 03:04, 30 August 2011

Pharmaceutical compound
Phentolamine
Clinical data
Trade namesRegitine
AHFS/Drugs.comMicromedex Detailed Consumer Information
Pregnancy
category
Routes of
administration		Usually IV or IM
ATC code
Pharmacokinetic data
MetabolismHepatic
Elimination half-life19 minutes
Identifiers
IUPAC name
  • 3-phenol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.049 Edit this at Wikidata
Chemical and physical data
FormulaC17H19N3O
Molar mass281.352 g/mol g·mol
3D model (JSmol)
SMILES
  • Oc3cc(N(c1ccc(cc1)C)CC/2=N/CCN\2)ccc3
InChI
  • InChI=1S/C17H19N3O/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15/h2-8,11,21H,9-10,12H2,1H3,(H,18,19)
  • Key:MRBDMNSDAVCSSF-UHFFFAOYSA-N
  (verify)

Phentolamine (Regitine) is a reversible nonselective alpha-adrenergic antagonist.

Mechanism

Its primary action is vasodilation due to α1 blockade.

It also can lead to reflex tachycardia because of hypotension and α2 inhibition, which increases sympathetic tone.

Uses

The primary application for phentolamine is for the control of hypertensive emergencies, most notably due to pheochromocytoma.

It also has usefulness in the treatment of cocaine induced hypertension, where one would generally avoid beta blockers and where calcium channel blockers are not effective. Beta-blockers (i.e. metoprolol) or combined alpha and beta adrenergic blocking agents (i.e. labetalol) should be avoided in patients with a history of cocaine abuse. They can cause an unopposed alpha-adrenergic mediated coronary vasoconstriction, causing the worsening of myocardial ischemia and hypertension.

In this context it is probably most safely given by infusion since bolus doses have a propensity towards causing precipitous falls in blood pressure.

When given by injection it causes blood vessels to expand, thereby increasing blood flow. When injected into the penis (intracavernosal), it increases blood flow to the penis, which results in an erection.

It may be stored in crash carts to counteract severe peripheral vasoconstriction secondary to extravasation of peripherally placed vasopressor infusions, typically of norepinephrine. Epinephrine infusions are less vasoconstrictive than norepinephrine as they primarily stimulate beta receptor more than alpha receptors, but the effect remains dose dependent.

Phentolamine also has diagnostic and therapeutic roles in complex regional pain syndrome (reflex sympathetic dystrophy).

Phentolamine has recently been introduced in the dental field as a local anesthetic reversal agent. Distributed by Septodont, OraVerse is a Phentolamine Mesylate injection designed to reverse the local vasoconstrictor properties used in many local anesthetics to prolong anesthesia. OraVerse has been shown to accelerate the reversal of the lingering soft-tissue numbness associated with the widely used anesthetic-vasoconstrictor combinations.

Chemistry

Phentolamine, 2-methyl]-2-imidazoline, is synthesized by alkylation of 3-(4-methylanilino)phenol using 2-chloromethylimidazoline.

  • K. Miescher, A. Marxer, E. Urech, U.S. patent 2,503,059 (1950).
  • E. Urech, A. Marxer, K. Miescher, Helv. Chim. Acta, 33, 1386 (1950).

References

  1. Jewell, John R.; Longworth, David L.; Stoller, James K.; Casey, David (2003). The Cleveland Clinic internal medicine case reviews. Hagerstown, MD: Lippincott Williams & Wilkins. p. 32. ISBN 0-7817-4266-8.{{cite book}}: CS1 maint: multiple names: authors list (link)
  2. Phentolamine at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
  3. Brock G. Oral phentolamine (Vasomax). Drugs Today (Barcelona). 2000 Feb-Mar;36(2-3):121-4.
  4. Shen, Howard (2008). Illustrated Pharmacology Memory Cards: PharMnemonics. Minireview. p. 14. ISBN 1-59541-101-1.
  5. Tuncel M, Ram VC. Hypertensive emergencies. Etiology and management. American Journal of Cardiovascular Drugs. 2003;3(1):21-31.
  6. Hollander JE, Henry TD. Evaluation and management of the patient who has cocaine-associated chest pain. Cardiology Clinics. 2006 Feb;24(1):103-14.
  7. Chan GM, Sharma R, Price D, Hoffman RS, Nelson LS. Phentolamine Therapy for Cocaine-Association Acute Coronary Syndrome (CAACS). Journal of Medical Toxicology. 2006 Sep;2(3):108-11.
  8. Bella AJ, Brock GB. Intracavernous pharmacotherapy for erectile dysfunction. Endocrine. 2004 Mar-Apr;23(2-3):149-55.
  9. Rowbotham MC. Pharmacologic management of complex regional pain syndrome. Clinical Journal of Pain. 2006 Jun;22(5):425-9.
  10. http://www.novalar.com/oraverse-dental-specialty-pharmaceutical
  11. Malamed S. What's new in local anaesthesia? Society For The Advancement Of Anaesthesia In Dentistry Digest. 2009 Jan;25:4-14.
Sympatholytic (and closely related) antihypertensives (C02)
Sympatholytics
(antagonize α-adrenergic
vasoconstriction)
Central
α2-Adrenergic receptor agonists
Adrenergic release inhibitors
Imidazoline receptor agonists
Ganglion-blocking/nicotinic antagonists
Peripheral
Indirect
Monoamine oxidase inhibitors
VMAT inhibitors
Tyrosine hydroxylase inhibitors
Direct
α1-Adrenergic receptor blockers
Non-selective α-adrenergic receptor blockers
Other antagonists
Serotonin receptor antagonists
Endothelin receptor antagonists (for PHTooltip Pulmonary hypertension)
Peripheral vasodilators (C04)
Phenylethanolamine derivatives
Alpha blockers
Niacin and derivatives
Purine derivatives
Ergot alkaloids
Other peripheral vasodilators
Drugs for erectile dysfunction (G04BE) and premature ejaculation
For erectile dysfunction
Prostaglandins (E)
PDE5 inhibitors
Alpha blockers
Dopamine agonists
Melanocortin agonists
Others
For premature ejaculation
SSRIs
Oxytocin antagonists
DRA/DRIs
Adrenergic receptor modulators
α1
Agonists
Antagonists
α2
Agonists
Antagonists
β
Agonists
Antagonists
Categories: